Research programme: Parkinson's disease therapeutics - TauRx Therapeutics

Drug Profile

Research programme: Parkinson's disease therapeutics - TauRx Therapeutics

Alternative Names: G2 PD; TRx 018

Latest Information Update: 01 Feb 2016

Price : $50

At a glance

  • Originator TauRx Therapeutics
  • Class
  • Mechanism of Action Synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 01 Feb 2016 Early research development is ongoing in Singapore (TauRx Therapeutics pipeline, February 2016)
  • 30 Jun 2011 Preclinical trials in Parkinson's disease in Singapore (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top